MarketLens
Sign Up

AbbVie and Genmab's Epcoritamab: Why the Lymphoma Breakthrough is Still Undervalued

4 months ago
SHARE THIS ON:

AbbVie and Genmab's Epcoritamab: Why the Lymphoma Breakthrough is Still Undervalued

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study

AbbVie and Genmab's combination treatment for newly diagnosed lymphoma reduced the risk of disease progression or death in a late-stage study, per a Monday announcement.
Stock News•2 months ago

AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next

AbbVie's immunology franchise is being driven by Skyrizi and Rinvoq, with new indications, acquisitions, and partnerships building the next wave of growth.
Stock News•4 months ago

Genmab: Multiple Late-Stage Readouts Ahead

Genmab shares have underperformed YTD despite strong Q2 royalty sales (Darzalex +18% Y/Y, Tecvayli +57% Y/Y). Up to five late-stage trial readouts for Epkinly, petosemtamab, and Rina-S are expected, s...

Breaking News

View All →

Top Headlines

View More →
Stock News•2 hours ago

Cisco Stock Fell 15.5% Despite Its Strongest Growth in 15 Years. Is the Dividend Safe?

Stock News•2 hours ago

Prediction: This Will Be Nvidia's Stock Price in 2027 After Its Phenomenal Q3 Results

Stock News•2 hours ago

GOOGL, GOOG FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Alphabet Inc. Investors to Secure Counsel Before Important December 1 Deadline in Securities Class Action - GOOGL, GOOG

Stock News•3 hours ago

The S&P 500 Is Now Below Every Wall Street Year-End Target for 2026

Stock News•3 hours ago

The S&P 500 Is Having the Longest Losing Streak Since February 2020